Abstract A032: Regorafenib–MEK inhibitor combination reshapes tumor cell states and reprograms the tumor microenvironment to enable immunotherapy in group 3 medulloblastoma
Year: 2026
Type: conference-abstract
Source: Cancer Immunology Research
Authors: JINGJING LIU, Mingrui Zhu, Xu Yang, Honglei Zhou, Amar Gajjar, Jiyang Yu
Institution: St. Jude Children's Research Hospital
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7130550486
Cites:
Cited by:
Related to: